COGNITION THERAPEUTICS INC

For the period ended Dec 31, 2024. Filed Mar 20, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 20, 2025

CGTX$0.69+0.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 20, 2025.


	COGNITION THERAPEUTICS, INC.

	By:	/s/ Lisa Ricciardi
		Lisa Ricciardi
		Chief Executive Officer, President and Director
		(Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on March 20, 2025 by the following persons on behalf of the registrant and in the capacities indicated:


Signature	Title	Date

/s/ Lisa Ricciardi	Chief Executive Officer, President and Director	March 20, 2025
Lisa Ricciardi	(Principal Executive Officer)

/s/ John Doyle	Chief Financial Officer	March 20, 2025
John Doyle	(Principal Financial and Accounting Officer)

/s/ Jack A. Khattar	Director (Chairman of the Board)	March 20, 2025
Jack A. Khattar

/s/ Aaron G. L. Fletcher, Ph.D.	Director	March 20, 2025
Aaron G. L. Fletcher, Ph.D.

/s/ Brett P. Monia, Ph.D.	Director	March 20, 2025
Brett P. Monia, Ph.D.

/s/ Ellen B. Richstone	Director	March 20, 2025
Ellen B. Richstone

/s/ Peggy Wallace	Director	March 20, 2025
Peggy Wallace

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.